JP2024540083A5 - - Google Patents

Info

Publication number
JP2024540083A5
JP2024540083A5 JP2024525338A JP2024525338A JP2024540083A5 JP 2024540083 A5 JP2024540083 A5 JP 2024540083A5 JP 2024525338 A JP2024525338 A JP 2024525338A JP 2024525338 A JP2024525338 A JP 2024525338A JP 2024540083 A5 JP2024540083 A5 JP 2024540083A5
Authority
JP
Japan
Prior art keywords
sequence
cancer
antigen
sequences
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078780 external-priority patent/WO2023076998A1/en
Publication of JP2024540083A publication Critical patent/JP2024540083A/ja
Publication of JP2024540083A5 publication Critical patent/JP2024540083A5/ja
Pending legal-status Critical Current

Links

JP2024525338A 2021-10-27 2022-10-27 抗NRP2a抗体を含む組成物及び方法 Pending JP2024540083A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272374P 2021-10-27 2021-10-27
US63/272,374 2021-10-27
PCT/US2022/078780 WO2023076998A1 (en) 2021-10-27 2022-10-27 COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2024540083A JP2024540083A (ja) 2024-10-31
JP2024540083A5 true JP2024540083A5 (cg-RX-API-DMAC7.html) 2025-08-28

Family

ID=86158721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525338A Pending JP2024540083A (ja) 2021-10-27 2022-10-27 抗NRP2a抗体を含む組成物及び方法

Country Status (7)

Country Link
US (1) US20240417476A1 (cg-RX-API-DMAC7.html)
EP (1) EP4423142A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540083A (cg-RX-API-DMAC7.html)
CN (1) CN118355033A (cg-RX-API-DMAC7.html)
AU (1) AU2022375785A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234409A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023076998A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
NZ594514A (en) * 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Aβオリゴマーに特異的に結合する抗体およびその利用
EP2700652B1 (en) * 2011-04-18 2018-12-19 The University of Tokyo Diagnosis and treatment of cancer using anti-itm2a antibody
DK2935331T3 (en) * 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
EP3116906A1 (en) * 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
US11104724B2 (en) * 2016-05-23 2021-08-31 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
US12365916B2 (en) * 2017-10-30 2025-07-22 Miltenyi Biotec B.V. & Co. KG Adapter-based retroviral vector system for the selective transduction of target cells
WO2019195770A1 (en) * 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
ES3049416T3 (en) * 2019-09-23 2025-12-16 Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P Antibodies for the diagnosis and/or treatment of atherosclerosis
AU2020358854B2 (en) * 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
WO2021202590A1 (en) * 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7379561B2 (ja) キメラ抗原及びt細胞受容体、並びに使用方法
JP2021521110A5 (cg-RX-API-DMAC7.html)
CN109843921B (zh) 程序性死亡1配体1(pd-l1)结合蛋白及其应用方法
JP7295795B2 (ja) 免疫調節ポリペプチドならびに関連する組成物および方法
JP2022551603A5 (cg-RX-API-DMAC7.html)
US20190048085A1 (en) Modified cells for immunotherapy
JP2020015753A (ja) Pd1および/またはlag3結合性物質
JP2021531313A5 (cg-RX-API-DMAC7.html)
JP2017511687A5 (cg-RX-API-DMAC7.html)
JP2020525005A5 (cg-RX-API-DMAC7.html)
CN113906049A (zh) 用于共施用针对c-kit和CD47的免疫治疗剂的方案
WO2021027785A1 (zh) 共表达趋化因子受体的免疫效应细胞
CN117586416A (zh) 双特异性嵌合抗原受体和免疫细胞、制备方法、应用及肿瘤治疗药品
EP4261277A2 (en) Methods of treating cancer and infectious diseases using cell based therapies
EP4182337B1 (en) Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
WO2025093035A1 (en) Cd40-targetting antibodies and uses thereof
WO2022033483A1 (zh) 多功能的免疫效应细胞及其应用
CN118126194A (zh) 靶向cd70的嵌合抗原受体
CN110004167A (zh) 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
WO2021115333A1 (zh) 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用
Vlaming Novel T cell biomarkers and the development of immunotherapeutic anti-tumor strategies
HK40068212A (en) Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
HK40103881A (en) Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
CN122011207A (zh) 过表达h2a.z的car-t细胞及其制备方法和应用
HK40009925A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof